4 results
Primary:Assess the safety of repeat doses of serelaxin in chronic heart failureSecondary:- Assess the incidence rate of adverse events of special interest, indicative of hypersensitivity reactions- Assess the safety and tolerability of repeated…
Primary Objective:To demonstrate that serelaxin is superior to placebo in reducing CV death in AHF patients during a follow-up period of 180 days.To demonstrate that serelaxin is superior to placebo in reducing worsening heart failure through Day…
Primary objective: To assess the effect of FDY-5301 on cardiovascular mortality and heart failure events in subjects with an anterior STEMI undergoing pPCI.Secondary objective:To assess the effect of FDY-5301 on other clinical outcomes such as all-…
Primary• To evaluate the safety and tolerability of single ascending IV doses of ANX105 in normal healthy participantsSecondary• To characterize the single-dose PD of ANX105• To characterize the single-dose PK of ANX105